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Conventional treatment for brain metastases (BM) is whole-brain radiotherapy (WBRT). Efficacy is poor. It might be increased by a
potent radiosensitiser such as gemcitabine which is believed to cross the disrupted blood–brain barrier. Primary objective of this
study was to determine the maximum tolerated dose (MTD) of twice weekly gemcitabine given concurrently with WBRT. Patients
with BM from carcinoma were included. The dose of WBRT was 30Gys (10 daily fractions). Gemcitabine was given 2–4h prior to
WBRT on days 1 and 8 for the first cohort of patients and then on days 1, 4, 8 and 11. Starting dose was 25mgm
 2, escalated by
12.5mgm
 2 increments. At least three patients were included per level. Dose limiting toxicity (DLT) was defined as grade 4
haematological or grade X3 nonhaematological toxicity. A total of 25 patients were included; 74% had a PS 1 (ECOG). In all, 23 had
non-small-cell lung cancer, six colorectal, four breast, two renal cell and one oesophageal carcinoma. A total of 92% had concurrent
extracranial disease. Six had single BM, 13 had two or three BM and six multiple. Up to 50mgm
 2 (level 4) no DLT was observed. At
62.5mgm
 2, one out of six patients developed DLT (thrombocytopenia-bleeding). The next dose level (75mgm
 2) was abandoned
after grade 4 bone marrow toxicity (fatal neutropenic sepsis) was seen in one out of two patients. So that the dose of 50mgm
 2 will
be taken forward for further study.
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Brain metastases (BM) occur in 20–40% of cancer patients during
the course of their illness and 50–75% of them have more than one
metastasis (Patchel, 2003). Except for very few cases where surgery
may be indicated, the mainstream accepted therapeutic modality is
whole brain radiotherapy (WBRT). Gamma-knife radiosurgery and
conformal radiotherapy are recent developments that may confer a
prognosis improvement to selected patients mostly in cases of
single BM and controlled extracranial disease. The prognosis of the
vast majority of patients who develop BM is poor. The median
survival for treated patients with WBRT is approximately 4 months
and the 1-year survival only 12% (Lagerwaard et al, 1999).
Chemotherapy is not usually given and if the patient is actually
receiving chemotherapy, it is often discontinued. This attitude has
been fostered by the theoretical difficulty of drugs to pass the
blood–brain barrier and achieve therapeutic significance in brain
micrometastases. This however is probably not the case with
macroscopic metastases. Brain metastases in patients with many
chemosensitive tumours (e.g. testicular cancer, lymphoma, chor-
iocarcinoma) are well known to respond to chemotherapy. A
recent study by Postmus et al (2000) in patients with small-cell
carcinoma and BM showed a 22% response rate to chemotherapy
alone. However, the combination of chemotherapy and radio-
therapy produced a 57% response rate and the control in the brain
disease in these patients was longer than in patients who received
only chemotherapy. A phase III study of early vs late WBRT with
concurrent cisplatin and vinorelbine in patients with non-small-
cell lung cancer (NSCLC) and BM was reported by Robinet et al
(2001). Patients were chemonaive and drugs were given at full
dose. Patients were randomised to receive WBRT 30Grays (Gy) in
10 fractions over 12 days after two cycles of chemotherapy or on
days 1–12 concurrently with chemotherapy. The grade 3–4
toxicities were similar and specifically neurotoxicity and toxic
deaths were comparable in both arms. The response rate to
chemotherapy (as judged in the patients randomised to delayed
WBRT) was 27%. Many other studies have shown that BM from a
number of primary sites can be equally chemosensitive as to areas
outside the brain (Van den Bent, 2003). The problem of perceived
resistance is probably due to the fact that BM usually develop as a
late event in patients already treated with many agents to which
resistance has already developed.
One of the most promising newer chemotherapeutic drugs is the
bifluorinated analogue of cytarabine, gemcitabine. Gemcitabine,
both as a single agent and in combination with cisplatin or other
agents achieves a significant response rate in NSCLC, head and
neck carcinoma, pancreatic, breast and gynaecologic cancer
(Carmichael, 1998). This tends to be accompanied by a favourable
toxicity profile.
Gemcitabine has also demonstrated activity in BM in patients
with carcinoma. Gridelli et al (1999) evaluated the efficacy of the
Received 12 October 2004; revised 6 January 2005; accepted 6 January
2005; published online 15 February 2005
*Correspondence: Dr A Maraveyas, Academic Department of Oncology,
Princess Royal Hospital, Saltshouse Road/Hull, East Yorkshire HU8 9HE,
UK; E-mail: A.Maraveyas@hull.ac.uk
British Journal of Cancer (2005) 92, 815–819
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sdrug in 30 patients with NSCLC who had already received
chemotherapy with a platinum compound. The authors observed
six partial responses, and two of them were in patients with BM.
In a further study by Ceribelli et al (2003), again in patients with
NSCLC but this time treated with cisplatin and gemcitabine, the
overall response rates in the Arm of gemcitabine at the standard
30min infusion (Arm A) and in the arm of gemcitabine at an
infusion rate of 10mgm
 2min
 1 (Arm B) were 26% (95%
confidence interval (95% CI), 10–42%) and 34% (95% CI, 17–
52%), respectively. In the patients who happened to have BM, it
was interesting to note a high response rate (67%) of BM in Arm B.
Toxicity was tolerable and comparable in the two arms. As a
radiosensitiser, gemcitabine has been used in patients with NSCLC,
pancreatic cancer, head and neck cancer and cervical cancer. There
are no data for the use of gemcitabine as a radiosensitiser in the
setting of BM.
The aim of the current study was to find the maximum tolerated
dose (MTD) of gemcitabine when given as a radiosensitiser on a
twice weekly schedule to patients with BM from carcinoma.
MATERIALS AND METHODS
Eligibility
Patients with histologically or cytologically confirmed carcinoma
and BM were eligible for the study provided that surgery was not
an option. Eligibility criteria also included an Eastern Cooperative
Oncology Group performance status of 0–2 and age X18 years.
Adequate haematologic function was required: a white blood count
of X3500cellsml
 1, a platelet count of X100000ml
 1, and a
haemoglobin level of X10gdl
 1. Also, serum bilirubin needed to
be below two times the upper limit of normal (ULN), ALT and AST
below three times ULN – ALT and AST could be elevated to five
times ULN in patients with known metastatic disease in the liver –
and creatinine below two times ULN.
Previous chemotherapy was allowed up to second line as long as
gemcitabine had not been used. Patients had to be stable on
steroids. Patients with seizures who were not stable on anti-
epileptic medication were excluded. No previous radiotherapy to
the brain of any form was allowed. No surgical procedure to the
brain and no confusion was allowed (correctable confusion
(hypercalcaemia, hyponatremia) with time to correct it and
documented adequate mini-mental test scoring was allowed). For
female subjects of childbearing potential, adequate contraception
during and 3 months post-treatment was required. Patients with
haemorrhagic metastases were excluded and patients allergic to
contrast material either underwent MRI as baseline study or were
excluded.
The protocol was approved by the Hull and East Yorkshire
Hospitals Ethics Committee. Written informed consent was
obtained from all patients prior to the participation in the study.
CT or MRI scan of the brain was necessary before the beginning
of treatment. It was repeated if possible 1 month after the end of
the treatment (6 weeks). Patients were withdrawn from the study if
they developed sudden neurological deterioration indicating
intracranial bleed, allergic reaction to the chemotherapy agent,
development of infection allowing continuation of RT but not of
chemotherapy and upon patient request.
Treatment
A conventional radiotherapy fractionation schedule was used
(30Gy in 10 fractions over 12 days). The radiotherapy to the whole
brain was planned by simulation and given by parallel opposed
right and left lateral portals using six megavoltage X-rays beams.
Gemcitabine was given, as an intravenous infusion over 30min,
2–4h prior to radiotherapy. If the absolute neutrophil count
(ANC) was X750cellsml
 1, the platelet count was X100000ml
 1
and the patient had no more than grade 2 nonhaematological
toxicity, the full dose was delivered. With an ANC of
X500cellsml
 1 but o 750cellsml
 1 and platelet count of
X75000ml
 1 but o 100000ml
 1, 75% of the dose was given.
Gemcitabine dose was omitted if platelet count dropped below
75000ml
 1, ANC dropped below 500cellsml
 1 or if the patient was
experiencing grade 3 or greater nonhaematological toxicity.
The Folstein mini-mental test (Folstein et al, 1975) was
undertaken at baseline and weekly while on treatment and 4-
weekly thereafter until the patient came off study due to
progression. It was used as a tool to monitor the cognition of
the patients and detect any potential side effects of the treatment to
their neurocognitive performance, especially in those who
achieved a radiological response or stabilisation of their brain
disease.
Study design
The starting dose of gemcitabine was 25mgm
 2 on days 1 and 8.
The next level was 25mgm
 2 on days 1, 4, 8 and 11 (Table 2).
For dose escalation, three assessable patients had to complete
their treatment and the first post-treatment month without a dose
limiting toxicity (DLT). Haematological toxicities were defined as
DLT if they were grade 4 at WHO scale. All other toxicities were
defined as DLT if they were grade X3 at the WHO scale. If no DLT
was experienced, then dose escalation could proceed and three
patients were enrolled at the next dose level. If two or more
patients experience DLT, then the MTD had been defined at this
dose level. When one DLT was seen, an additional three assessable
patients had to be accrued, and further escalation could occur if no
additional DLT were seen. Once the MTD was established, the
phase II dose level was defined as the dose level before MTD was
reached.
Response assessment
Response was assessed by repeat CT or MRI scan of the brain 4
weeks after the end of the treatment. We determined response by
using the response evaluation criteria in solid tumours group
(RECIST) criteria (Therasse et al, 2000). Complete response (CR)
was defined as disappearance of all target and nontarget tumour
lesions and partial response (PR) as a 30% or greater decrease in
the sum of the longest diameter of all target lesions together with
stabilisation or decrease in size of nontarget lesions. Disease
progression (PD) required a X20% increase in the sum of the
longest diameter of target lesions, an unequivocal increase in the
nontarget lesions or appearance of any new lesions. Stable disease
was defined as insufficient tumour shrinkage to qualify for PR and
insufficient increase in tumour size to qualify for PD. It has to be
noted that the study did not stipulate a further scan 4 weeks later
(i.e. 8 weeks post-treatment ) to confirm response in responding
patients.
RESULTS
Patients characteristics
Between February 2001 and July 2003, 25 patients were included in
this phase I study. As shown in Table 1, the most common type of
cancer was NSCLC, followed by colorectal and breast cancer. In all,
76% of patients had more than one brain metastasis and almost all
of them had active malignant disease outside brain (92%). All of
them were on oral steroids (dexamethasone). The daily dose
ranged from 2 to 16mg (median dose 12mgday
 1) and it
remained stable while patients received the study treatment. Two
patients were also on oral phenytoin 300mgday
 1.
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Six different doses of gemcitabine were studied. Patients included
at the first level of treatment had their gemcitabine doses once per
week. All other patients received the chemotherapy drug twice
weekly. Overall, 84 doses of gemcitabine were given and the
median number per patient was four. Doses up to 37.5mgm
 2
were very well tolerated without any signs of significant toxicity.
As it can be seen in Table 2 at the dose of 50mgm
 2, no DLT has
occurred but four out of seven patients needed dose reduction
during their treatment. The toxicity that caused dose reduction
of the drug was in all cases thrombocytopenia grade 2 during
the second week of treatment (third and/or fourth dose of
gemcitabine).
At the dose of 62.5mgm
 2, one patient developed bone-
marrow-related DLT. Neutropenia and thrombocytopenia grade
4 occurred in one of the first three patients treated at this dose.
This patient suffered from oesophageal cancer and she was
hospitalised but died during the second week of treatment from
uncontrolled lower GI bleeding. No further DLTs were seen at this
level, but one patient needed a dose reduction due to thrombo-
cytopenia grade 2 and another one developed grade 3 thrombo-
cytopenia after the end of treatment.
Two further patients were treated at the gemcitabine dose of
75mgm
 2 and one of them developed grade 4 neutropenia and
fatal neutropenic sepsis immediately after the end of treatment.
Haematological toxicities are summarised in Table 3. Given the
experience at the previous dose level and the further toxicity
seen in one patient at dose level 6 (75mgm
 2), it was decided
that the MTD had been reached at dose level 5 (62.5mgm
 2)
and the study of further patients at dose level 6 was
abandoned. Therefore, dose level 4 (50mgm
 2) is the dose to
be taken forward to a phase II study. At this dose level, four of
seven patients needed dose adjustment of the third and or
fourth dose but no greater than grade 2 bone marrow toxicity
was noted.
No significant nonhaematological toxicities were observed at
any dose level. In particular, no deterioration of the cognitive
function of the responding patients was found by using the mini-
mental status examination (MMSE). At the beginning of treatment,
the average score of patients in the MMSE was 28.5 (range 24–30)
with 30 being the maximum score that someone can achieve in
the examination. Just after the completion of the treatment
the mean score was 28.25 (range 25–30), while at 3 months the
median score for six patients who responded to treatment was 29.6
(range 28–30).
Table 1 Patient characteristics (N¼25)
Variable
Number of patients
n %
Age (years)
Median 57 —
Range 41–76 —
Gender
Male 15 60
Female 10 40
Performance Status
06 2 4
11 8 7 2
21 4
Type of cancer
NSCLC
a 12 48
Colorectal 6 24
Breast 4 16
Other (renal cell and oesophageal) 3 12
Number of brain metastases
16 2 4
2 or 3 13 52
4 or more 6 24
Extracranial disease
Yes 23 92
No 2 8
Previous chemotherapy
Yes 12 48
No 13 52
aNSCLC¼non-small-cell lung cancer.
Table 2 Dose limiting toxicities (DLTs) and occurrence of toxicities
necessitating dose reduction or dose omission by the seven dose levels of
gemcitabine tested
Gemcitabine
dose
Number of
patients treated
Number of
patients needed
reduction or
omission of at
least one dose
Number of
patients with a
DLT
25mgm
 2 weekly 4 0 0
25mgm
 2 twice
weekly
320
37.5mgm
 2 twice
weekly
300
50mgm
 2 twice
weekly
740
62.5mgm
 2 twice
weekly
621
75mgm
 2 twice
weekly
211
Table 3 Haematological toxicities as occurred among 25 treated patients by the seven dose levels of gemcitabine tested
Gemcitabine dose Number of patients treated
Neutropenia (number of patients) Thrombocytopenia (number of patients)
Grade 2 Grade 3 Grade 4 Grade 2 Grade 3 Grade 4
25mgm
 2 weekly 4 1 0 0 1 0 0
25mgm
 2 twice weekly 3 0 0 0 0 0 0
37.5mgm
 2 twice weekly 3 0 0 0 0 0 0
50mgm
 2 twice weekly 7 0 0 0 3 0 0
62.5mgm
 2 twice weekly 6 0 0 1 1 1 1
75mgm
 2 twice weekly 2 0 0 1 0 1 0
Gemcitabine as a radiosensitiser in brain metastases
A Maraveyas et al
817
British Journal of Cancer (2005) 92(5), 815–819 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sResponse rate and survival
Although the aim of this study was not to provide data on these
end points, we can report that 12 patients died within the first 2
months from the beginning of treatment and 11 patients were alive
more than 5 months later. There were two treatment-related deaths
at the two higher dose levels. Of the 13 patients who were alive at 2
months, 11 had a repeated radiological evaluation of their
metastatic brain disease. One patient with metastatic rectal cancer
showed a complete response (gemcitabine dose 50mgm
 2), six
patients partial response (four at low doses of gemcitabine, one at
62.5mgm
 2 and one at the 75mgm
 2 level). In total, three
patients had stabilisation of their brain disease.
DISCUSSION
The results of our phase I study of WBRT with gemcitabine used in
a twice weekly schedule as a radiosensitiser in cancer patients with
BM is presented.
Gemcitabine was chosen for this study, as it is a potent
radiosensitiser in vitro and in vivo. The retention of the cytotoxic
gemcitabine diphosphate (dFdCTP) in cells with a terminal
elimination time as long as 72h is probably a major factor
determining this property. The radiosensitisation usually occurs
under conditions where cancer cell lines demonstrate a concurrent
redistribution in S phase. At this point, depletion of dATP pools
(due to ribonucleotide reductase inhibition produced by the drug)
leads to misincorporation and misrepair of incorrect bases after
radiation (McGinn and Lawrence, 2001; Lawrence et al, 2003). It
has also been suggested that apoptosis contributes to the radio-
sensitisation of gemcitabine (Lawrence et al, 2001).
These conditions can be reproduced by (i) a long (24h)
exposure to a low concentration of gemcitabine (10nmol
 l) or (ii)
by a brief 2-h treatment with higher but clinically relevant
concentrations (100nmol
 l1–3mmol
 l) (Lawrence et al, 1997). In
the second situation, radiosensitisation can be detected 4h after
treatment and can last for 2 days. It is suggested that the active
metabolite dFdCTP needs to be present at the time of radiation to
potentiate the radiation effects. A twice weekly dosing therefore or
a slower rate infusion (10mgm
 2min
 1) are likely to be preferable
as radiosensitisation strategies.
The administration schedule has a profound effect on the
gemcitabine dose. This probably again relates to the fact that
incorporation of the active metabolite dFdCTP is a saturable
process with a prolonged intracellular retention time.
A weekly 30min infusion can be dosed to up to 2.200mgm
 2.
Currently, the clinical use of gemcitabine as a weekly single agent is
between 1000 and 1250mgm
 2. Changing the schedule to twice
weekly dosing at the same infusion rate reduces the dose per
administration by an order of magnitude. The MTD for twice
weekly dosing for 30min infusions was 65–90mgm
 2 (Poplin et al,
1992; Lund et al, 1994). Interestingly, a review of safety and efficacy
data of all European and US studies comparing twice weekly to
weekly administration concluded that the actual response rates
were similar (Martin et al, 1996). However, the twice weekly
schedule was not recommended for general use as the reviewers
concluded that it caused more ‘flu like’ side-effects (63.3 vs 19.8%).
We have demonstrated that gemcitabine on a twice weekly
schedule with WBRT can be given at a dose of 50mgm
 2. This
dose is lower than that reported for single agent gemcitabine
(90mgm
 2), probably due to the radiotherapy effect despite the
fact that the axial skeleton was not irradiated. Similarly to our
study, the addition of radiotherapy (to the abdomen for pancreatic
cancer) reduced the twice weekly dose further to 40mgm
 2
(Blackstock et al, 1999). These investigators administered gemci-
tabine for 5 weeks and the fractionation schedule was 45Gy in
1.8Gy daily fractions with a further 5.4Gy boost. Interestingly even
the dose of 60mgm
 2 used by Blackstock et al (1999) had
relatively modest toxicity (only grade 3 bone marrow toxicity
noted). In our case, the dose of 62.5mgm
 2 had at least one case of
severe toxicity. Both in this study and our study, platelet count
reduction was the most common toxicity. Although we saw no
nonhaematological toxicity, it has to be noted that other studies
have shown that depending on the area of irradiation this should
be expected. In a study of weekly gemcitabine in head and neck
cancer patients (Eisbruch et al, 2001), the DLT was severe mucosal
and pharyngeal toxicity while in patients with NSCLC DLT was
oesophagitis and pulmonary actinic interstitial disease (Trodella
et al, 2002). We noticed no deterioration in mental function as
tested by the Felstein test that could be attributed to treatment
despite having patients alive at 15 and 17 months. Nevertheless the
majority of the patients had short survival, therefore strong
conclusions about potential remote neurological toxicity cannot be
drawn especially without a randomised control group for
comparison. In contrast to the study by Martin et al (1996), we
saw no evidence of prominent flu-like symptoms in any of our
patients. We have to note, however, that our patients were on high
dose (median dose of 12mgday
 1) of dexamethasone which may
have abrogated this side effect.
To date a number of potential radiosensitising agents such as
metallotexaphyrins, synthetic allosteric modifiers of haemoglobin
or other chemotherapeutic drugs have been used without a
demonstrable improvement in survival of patients with BM
(Komarnicky et al, 1991; Phillips et al, 1995; Mehta et al, 2003).
Therefore, the investigation of newer promising agents needs to
continue.
It would not be safe to reach any conclusions about the efficacy
of the addition of gemcitabine as a radiosensitiser to the WBRT.
The 44% 5-month survival observed needs to be challenged in a
future phase III study comparing the combination with WBRT
alone.
We have therefore defined that the MTD of gemcitabine at this
schedule in patients with BM is 62.5m
 2, and a phase II study with
gemcitabine given twice weekly at the preceding dose level of
50mgm
 2 as a radiosensitiser to WBRT is already in progress at
our centre.
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